Author:
Segura-Aguilar Juan,Paris Irmgard
Publisher
Springer International Publishing
Reference199 articles.
1. Abbas, N., Lücking, C. B., Ricard, S., Dürr, A., Bonifati, V., De Michele, G., Bouley, S., Vaughan, J. R., Gasser, T., Marconi, R., Broussolle, E., Brefel-Courbon, C., Harhangi, B. S., Oostra, B. A., Fabrizio, E., Böhme, G. A., Pradier, L., Wood, N. W., Filla, A., … Brice, A. (1999). A wide variety of mutations in the Parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson’s Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson’s Disease. Human Molecular Genetics, 8(4), 567–574. https://doi.org/10.1093/hmg/8.4.567
2. Aguirre, P., Urrutia, P., Tapia, V., Villa, M., Paris, I., Segura-Aguilar, J., & Núñez, M. T. (2012). The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals: An International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine, 25(4), 795–803. https://doi.org/10.1007/s10534-012-9525-y
3. Akhtar, M. J., Yar, M. S., Grover, G., & Nath, R. (2020). Neurological and psychiatric management using COMT inhibitors: A review. Bioorganic Chemistry, 94, 103418.
4. Anoz-Carbonell, E., Timson, D. J., Pey, A. L., & Medina, M. (2020). The catalytic cycle of the antioxidant and cancer-associated human NQO1 enzyme: Hydride transfer, conformational dynamics and functional cooperativity. Antioxidants (Basel, Switzerland), 9(9), 772.
5. Arriagada, C., Paris, I., Sanchez de las Matas, M. J., Martinez-Alvarado, P., Cardenas, S., Castañeda, P., Graumann, R., Perez-Pastene, C., Olea-Azar, C., Couve, E., Herrero, M. T., Caviedes, P., & Segura-Aguilar, J. (2004). On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: Mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiology of Disease, 16(2), 468–477. https://doi.org/10.1016/j.nbd.2004.03.014